$2.90 per share would value Pfizer stock at less than 9 times earnings, Pfizer pays a 6.5% dividend yield -- and hasn't cut ...

For the full year of 2025, Pfizer posted revenue of 62.6 billion dollars and an adjusted diluted EPS of 3.22 dollars, beating the consensus estimates polled by FactSet, which had anticipated revenue ...

An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.

The pipeline remains critical in determining Pfizer’s ability to pull itself out of a declining top line, but the $4.4 ...

The effectiveness of last season's COVID vaccines among immunocompetent adults reached 40% against hospitalization and 79% ...

As 2025 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera's obesity assets.

Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend ...

The recommended childhood and adolescent immunization schedule for the United States for 2026 has been issued by the AAP.

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues.

Feb 3 (Reuters) - Pfizer on Tuesday reported fourth-quarter ‌earnings ​above Wall Street estimates, ‌as sustained demand for older drugs such as blood ​thinner Eliquis helped offset fading sales of ...